Japan Approves CSL and Arcturus’ Updated mRNA COVID-19 Vaccine for JN.1 Strain

CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics have announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved their updated self-amplifying mRNA (sa-mRNA) COVID-19 vaccine, KOSTAIVE®. The new vaccine is designed to protect against the JN.1 lineage of Omicron…

Read MoreJapan Approves CSL and Arcturus’ Updated mRNA COVID-19 Vaccine for JN.1 Strain

Advanced eClinical Training and The Education Fund Partner to Enhance Healthcare Worker Education

Advanced eClinical Training (ACT), a top provider of online career certification, has joined forces with the SEIU-UHW West & Joint Employer Education Fund (The Education Fund), which offers employer-funded education, training, and career support for union members in healthcare. This…

Read MoreAdvanced eClinical Training and The Education Fund Partner to Enhance Healthcare Worker Education

ENHERTU® Shows Strong Clinical Activity in HER2+ Metastatic Breast Cancer with Brain Metastases

Results from the DESTINY-Breast12 phase 3b/4 trial reveal that ENHERTU® (trastuzumab deruxtecan) demonstrated significant clinical activity in HER2-positive metastatic breast cancer patients with brain metastases who had received up to two prior lines of therapy. These findings will be presented…

Read MoreENHERTU® Shows Strong Clinical Activity in HER2+ Metastatic Breast Cancer with Brain Metastases

LifestyledAI, Dongguk University, and UMUST R&D Partner to Drive Global AI and Healthcare Innovation

On August 28, 2024, Dongguk University Startup Technology Institute, LifestyledAI Co., Ltd., and UMUST R&D signed a joint MOU to collaborate on advancing global deep tech and healthcare initiatives. The partnership will leverage LifestyledAI’s innovative, proprietary AI technologies, currently patent-pending,…

Read MoreLifestyledAI, Dongguk University, and UMUST R&D Partner to Drive Global AI and Healthcare Innovation

Massive Bio and Foundation Medicine Partner to Enhance Cancer Clinical Trial Access

Massive Bio, an AI-powered clinical trial matching platform, and Foundation Medicine have announced a strategic partnership to expand patient access to advanced clinical trials. The collaboration combines Massive Bio’s patient-matching technology with Foundation Medicine’s expertise in next-generation sequencing (NGS) and…

Read MoreMassive Bio and Foundation Medicine Partner to Enhance Cancer Clinical Trial Access

FDA Approves Ocrevus Zunovo™: First Twice-Yearly 10-Minute Injection for MS

Genentech, part of the Roche Group, announced that the U.S. FDA has approved Ocrevus Zunovo™ (ocrelizumab & hyaluronidase-ocsq) for treating relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). Ocrevus Zunovo is the first twice-yearly, 10-minute subcutaneous injection administered…

Read MoreFDA Approves Ocrevus Zunovo™: First Twice-Yearly 10-Minute Injection for MS

Neuraptive Receives FDA Breakthrough Designation for NTX-001 and Updates on Peripheral Nerve Injury Treatment

Neuraptive Therapeutics, Inc. has announced that its therapy NTX-001 has received Breakthrough Therapy Designation from the FDA, which could accelerate its development for patients with peripheral nerve injuries that need repair. This designation is based on promising results from the…

Read MoreNeuraptive Receives FDA Breakthrough Designation for NTX-001 and Updates on Peripheral Nerve Injury Treatment